NASDAQ:VRAY ViewRay (VRAY) Stock Forecast, Price & News $0.53 0.00 (0.00%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$0.53▼$0.5850-Day Range$0.53▼$3.5052-Week Range$0.51▼$4.96Volume3.09 million shsAverage Volume2.79 million shsMarket Capitalization$97.17 millionP/E RatioN/ADividend YieldN/APrice Target$3.18 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ViewRay MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside500.0% Upside$3.18 Price TargetShort InterestHealthy4.01% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.63Based on 3 Articles This WeekInsider TradingSelling Shares$173,460 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.58) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector150th out of 1,012 stocksElectromedical Equipment Industry3rd out of 22 stocks 4.1 Analyst's Opinion Consensus RatingViewRay has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.18, ViewRay has a forecasted upside of 500.0% from its current price of $0.53.Amount of Analyst CoverageViewRay has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.01% of the float of ViewRay has been sold short.Short Interest Ratio / Days to CoverViewRay has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ViewRay has recently increased by 0.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldViewRay does not currently pay a dividend.Dividend GrowthViewRay does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreViewRay has received a 77.72% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "MRI machines", "Radiation therapy machines", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for ViewRay is -0.85. Previous Next 1.5 News and Social Media Coverage News SentimentViewRay has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ViewRay this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for VRAY on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ViewRay to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ViewRay insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,460.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of ViewRay is held by insiders.Percentage Held by Institutions84.40% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ViewRay are expected to grow in the coming year, from ($0.58) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ViewRay is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ViewRay is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViewRay has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ViewRay (NASDAQ:VRAY) StockViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.Read More Receive VRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter. Email Address VRAY Stock News HeadlinesMay 26, 2023 | fool.comViewRay (NASDAQ: VRAY)May 25, 2023 | markets.businessinsider.comViewray (VRAY) Receives a Hold from Stifel NicolausMay 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 20, 2023 | americanbankingnews.comViewRay (NASDAQ:VRAY) Research Coverage Started at StockNews.comMay 17, 2023 | americanbankingnews.comViewRay, Inc. (NASDAQ:VRAY) Receives $2.54 Average PT from BrokeragesMay 16, 2023 | finance.yahoo.comDo You Believe in the Growth Prospects of ViewRay (VRAY)?May 16, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for ViewRay, Inc. Decreased by B. Riley (NASDAQ:VRAY)May 14, 2023 | americanbankingnews.comStifel Nicolaus Lowers ViewRay (NASDAQ:VRAY) Price Target to $1.00May 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 14, 2023 | americanbankingnews.comViewRay, Inc. (NASDAQ:VRAY) Short Interest Down 30.1% in AprilMay 13, 2023 | msn.comMorgan Stanley Maintains ViewRay (VRAY) Equal-Weight RecommendationMay 12, 2023 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its ViewRay, Inc. (NASDAQ:VRAY) Estimates For 2023May 12, 2023 | finance.yahoo.comViewRay's MRIdian® to be Featured at Leading European Radiation Oncology MeetingMay 11, 2023 | finanznachrichten.deViewRay, Inc.: ViewRay Announces First Quarter 2023 ResultsMay 11, 2023 | markets.businessinsider.comB.Riley Financial downgrades Viewray (VRAY) to a HoldMay 11, 2023 | msn.comB. Riley Securities Downgrades ViewRay (VRAY)May 11, 2023 | msn.comViewRay hits 52-week low after pulling guidanceMay 11, 2023 | americanbankingnews.comViewRay (NASDAQ:VRAY) Downgraded by B. RileyMay 11, 2023 | markets.businessinsider.comBTIG Remains a Hold on Viewray (VRAY)May 10, 2023 | finance.yahoo.comViewRay Announces First Quarter 2023 ResultsMay 9, 2023 | finance.yahoo.comViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023April 27, 2023 | americanbankingnews.comViewRay (NASDAQ:VRAY) PT Lowered to $2.00 at Piper SandlerApril 24, 2023 | americanbankingnews.comViewRay, Inc. (NASDAQ:VRAY) Given Average Rating of "Hold" by BrokeragesApril 19, 2023 | americanbankingnews.comViewRay, Inc. to Post Q3 2023 Earnings of ($0.14) Per Share, Jefferies Financial Group Forecasts (NASDAQ:VRAY)April 18, 2023 | msn.comJefferies Downgrades Viewray (VRAY)April 17, 2023 | markets.businessinsider.comJefferies downgrades Viewray (VRAY) to a HoldApril 17, 2023 | finance.yahoo.comIt's Down 63% But ViewRay, Inc. (NASDAQ:VRAY) Could Be Riskier Than It LooksSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter. Email Address VRAY Company Calendar Last Earnings5/10/2023Today5/28/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRAY CUSIPN/A CIK1597313 Webwww.viewray.com Phone(440) 703-3210Fax800-417-3459Employees267Year Founded2004Price Target and Rating Average Stock Price Forecast$3.18 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+500.0%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-107,330,000.00 Net Margins-104.30% Pretax Margin-104.30% Return on Equity-120.48% Return on Assets-42.39% Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio0.91 Sales & Book Value Annual Sales$102.21 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book1.77Miscellaneous Outstanding Shares183,400,000Free Float178,817,000Market Cap$97.17 million OptionableOptionable Beta0.91 Social Links Key ExecutivesScott William DrakePresident, Chief Executive Officer & DirectorDrew HillSenior Vice President-Operations & DevelopmentWilliam Patrick BurkeChief Financial Officer & Executive Vice PresidentJames F. DempseyChief Scientific OfficerMartin FussChief Medical OfficerKey CompetitorsFONARNASDAQ:FONRBioSig TechnologiesNASDAQ:BSGMElectromedNYSE:ELMDHyperfineNASDAQ:HYPRVivani MedicalNASDAQ:VANIView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundSold 68,261 shares on 5/18/2023Ownership: 0.361%JPMorgan Chase & Co.Sold 235,071 shares on 5/18/2023Ownership: 0.064%B. Riley Wealth Advisors Inc.Bought 16,500 shares on 5/17/2023Ownership: 0.009%Geode Capital Management LLCBought 97,462 shares on 5/16/2023Ownership: 1.541%Jane Street Group LLCSold 187,800 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VRAY Stock - Frequently Asked Questions Should I buy or sell ViewRay stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares. View VRAY analyst ratings or view top-rated stocks. What is ViewRay's stock price forecast for 2023? 7 brokers have issued twelve-month price objectives for ViewRay's stock. Their VRAY share price forecasts range from $1.00 to $8.00. On average, they predict the company's stock price to reach $3.18 in the next year. This suggests a possible upside of 500.0% from the stock's current price. View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts. How have VRAY shares performed in 2023? ViewRay's stock was trading at $4.48 on January 1st, 2023. Since then, VRAY stock has decreased by 88.2% and is now trading at $0.5298. View the best growth stocks for 2023 here. When is ViewRay's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our VRAY earnings forecast. How were ViewRay's earnings last quarter? ViewRay, Inc. (NASDAQ:VRAY) released its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The business had revenue of $22.53 million for the quarter, compared to analyst estimates of $22.64 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%. What ETFs hold ViewRay's stock? ETFs with the largest weight of ViewRay (NASDAQ:VRAY) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI), What guidance has ViewRay issued on next quarter's earnings? ViewRay issued an update on its FY 2023 earnings guidance on Tuesday, April, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $102.21 million-$117.54 million, compared to the consensus revenue estimate of $136.37 million. What is Scott Drake's approval rating as ViewRay's CEO? 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ViewRay own? Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB). When did ViewRay IPO? (VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers. What is ViewRay's stock symbol? ViewRay trades on the NASDAQ under the ticker symbol "VRAY." Who are ViewRay's major shareholders? ViewRay's stock is owned by many different retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (8.44%), Fosun International Ltd (6.60%), BlackRock Inc. (5.81%), Neuberger Berman Group LLC (5.63%), FMR LLC (2.90%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen. View institutional ownership trends. How do I buy shares of ViewRay? Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ViewRay's stock price today? One share of VRAY stock can currently be purchased for approximately $0.53. How much money does ViewRay make? ViewRay (NASDAQ:VRAY) has a market capitalization of $97.17 million and generates $102.21 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. How many employees does ViewRay have? The company employs 267 workers across the globe. Does ViewRay have any subsidiaries? The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..Read More How can I contact ViewRay? ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459. This page (NASDAQ:VRAY) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViewRay, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.